Skip to content

Study · Not a test of the peptide alone · 2016

5 results

The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.

Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y

Diabetes, obesity & metabolism8 Sept 2016Cited by 7 (Europe PMC)

PMID27488246 (opens in a new tab)PMCIDPMC5129571 (opens in a new tab)DOI10.1111/dom.12758 (opens in a new tab)PepBankPUB-27488246
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    HbA1c changes had no clinically relevant differences across dulaglutide groups receiving sulphonylurea, biguanide, or both.

    In plain wordsHbA1c changes were similar across dulaglutide regimens with sulphonylurea, biguanide, or both.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change across background therapies
    Study

    n: not reported in source

    Comparator
    Dulaglutide with sulphonylurea, biguanide, or both
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    There were no clinically relevant differences in glycated haemoglobin (HbA1c) changes among the three subgroups in the dulaglutide group;
    3 context sentences
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents.
    Summary · context
    This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361).
    Summary · context
    The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    Japanese patients receiving dulaglutide with biguanide alone lost weight.

    In plain wordsPatients receiving dulaglutide with biguanide alone lost weight.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight with biguanide
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG.
    3 context sentences
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents.
    Summary · context
    This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361).
    Summary · context
    The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    Japanese patients receiving dulaglutide with sulphonylurea and biguanide lost weight.

    In plain wordsPatients receiving dulaglutide with sulphonylurea and biguanide lost weight.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight with sulphonylurea and biguanide
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Weight loss was observed with dulaglutide in combination with BG alone or with SU + BG.
    3 context sentences
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents.
    Summary · context
    This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361).
    Summary · context
    The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    Adverse event incidence did not differ significantly across dulaglutide background-therapy subgroups.

    In plain wordsSide effect rates did not differ significantly across dulaglutide background-therapy groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeAdverse events across background therapies
    Study

    n: not reported in source

    Comparator
    Other dulaglutide background-therapy subgroups
    Analysis
    Exploratory
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    The incidence of adverse events among subgroups was significantly different in the glargine group but not in the dulaglutide group.
    3 context sentences
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents.
    Summary · context
    This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361).
    Summary · context
    The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  5. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome

    Hypoglycaemia incidence was highest with concomitant sulphonylurea for both dulaglutide and glargine.

    In plain wordsLow blood sugar was most frequent with a sulphonylurea added, for both dulaglutide and glargine.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHypoglycaemia with concomitant sulphonylurea
    Study

    n: not reported in source

    Comparator
    Other concomitant-therapy subgroups
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Incidence of hypoglycaemia was highest in combination with SU for both treatments.
    3 context sentences
    Summary · context
    The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined.
    Summary · context
    The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents.
    Summary · context
    This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361).

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.